On statins: a race-related update

It is relatively common knowledge — although never actually proven in a large, randomized, placebo-controlled trial — that statins like rosuvastatin (Crestor) and atorvastatin (Lipitor) may be helpful in the management of prostate cancer. … READ MORE …

SBRT has equivalent toxicity with 5 treatments and 12 treatments: an update

We first reported data from the results of the RTOG 0938 trial in January 2016 when they were presented at the Genitourinary Cancers Symposium in that year. These results have now been formally published, and there are some changes to the data on publication, so Allen Edel has provided an update. … READ MORE …

Some recent videos on the UroToday web site

One has to sign up to become a member of the UroToday web site, but there is no cost involved, and an attractive feature for prostate cancer patients is the regular, relatively brief, video-recorded interviews with experts on recent, specific issues. … READ MORE …

VTP in the focal therapy of low-risk, localized prostate cancer

We have previously reported data from the 2-year follow-up of the patients participating in the PCM301 trial of vascular targeted phototherapy (VTP) — a form of prostate hemiablation — compared to active surveillance in the treatment of low-risk, localized prostate cancer. New data at 4 years of follow-up have now been published in the Journal of Urology. … READ MORE …

Targeted HIFU in the treatment of index lesions in localized prostate cancer

A new review article offers us some greater clarity related to the role of targeted, high-intensity focused ultrasound (HIFU) to treat carefully selected areas of the prostate to eliminate primary or index lesions while leaving the remainder of the prostate intact. … READ MORE …

What’s in the news from ASCO this year?

So there is no “revolutionary news” in relation to prostate cancer being presented at the annual meeting of the American Society of Medical Oncology (ASCO) in Chicago this year: no results of major phase III trials and no other critical new data that is likely to change physicians’ current practices when they get back home to their clinics. … READ MORE …

FDA approves new form of abiraterone acetate for treatment of prostate cancer

On May 23, the US Food and Drug Administration apparently approved a new formulation of abiraterone acetate, known as Yonsa®, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …